DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05916560

CompletedPhase 1

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

5

Recruiting sites

—

Enrollment

43

actual

Study population

Healthy volunteers, Hepatic impairment

Key I/E criteria

•BMI 19-42•Healthy volunteers

Primary endpoints

•AUC•PK: Maximum observed concentration (Cmax) of LY3437943

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05916560
Org study ID18531
Secondary IDJ1I-MC-GZBTEli Lilly and Company

Timeline

Milestones

Study first posted2023-06-23actual
Study start2023-07-13actual
Primary completion2025-03-02actual
Study completion2025-03-02actual
Last update posted2025-04-18actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Healthy volunteersHepatic impairment

Eligibility

Who can enroll

Minimum age18 Years
Maximum age85 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

All Participants:

•Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
•Healthy or various degrees of hepatic impairment depending on the study group

Exclusion criteria

Participants with hepatic impairment:

•Have or are anticipating an organ transplant within the next 6 months
•Requires needle evacuation of ascites fluid more than 2 times per month
•Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943

Time frame:Predose up to 30 days postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Maximum observed concentration (Cmax) of LY3437943

Time frame:Predose up to 30 days postdose

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.